Total Ankle Arthroplasty

Aetna considers total ankle arthroplasty (TAA) with an FDA‑cleared implant medically necessary to replace an arthritic or severely degenerated ankle in skeletally mature patients with moderate‑to‑severe pain and loss of ankle mobility/function due to osteoarthritis, post‑traumatic arthritis, or rheumatoid arthritis who have failed at least 6 months of conservative management (e.g., physical therapy, NSAIDs, orthoses). TAA is experimental/investigational (not covered) for all other indications, including combined TAA with total talar prosthesis, intra‑operative fresh frozen section infection analysis during TAA, patient‑specific instrumentation for TAA, and trans‑fibular TAA.

"L97."

Sign up to see full coverage criteria, indications, and limitations.